Drugmakers Clinch Deals to Boost Supplies of Pfizer’s Covid Pill

78
4
Favorite

Drugmakers Clinch Deals to Boost Supplies of Pfizer’s Covid Pill

Bloomberg2022-03-17

About three dozen drugmakers will produce low-cost versions of Pfizer Inc.’s Covid-19 pill as part of an effort to expand supplies of the highly effective drug in lower-income regions.Those companies,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（4）

fhho32
·2022-03-17
Agree
Reply
1
Report
HuatKueh313
·2022-03-17
Pls like
Reply
1
Report
QQChai
·2022-03-17
Please like
Reply
1
Report
manickam
·2022-03-17
Like
Reply
1
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1104468332?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-03-17 22:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1104468332","market":"us","top_or_hot":-1,"title":"Drugmakers Clinch Deals to Boost Supplies of Pfizer’s Covid Pill","media":"Bloomberg","content":"<div>\n<p>About three dozen drugmakers will produce low-cost versions of Pfizer Inc.’s Covid-19 pill as part of an effort to expand supplies of the highly effective drug in lower-income regions.Those companies,...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2022-03-17/drugmakers-clinch-deals-to-boost-supplies-of-pfizer-s-covid-pill?srnd=premium-asia\">Source Link</a>\n\n</div>\n","source":"lsy1584095487587","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Drugmakers Clinch Deals to Boost Supplies of Pfizer’s Covid Pill</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDrugmakers Clinch Deals to Boost Supplies of Pfizer’s Covid Pill\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-17 22:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2022-03-17/drugmakers-clinch-deals-to-boost-supplies-of-pfizer-s-covid-pill?srnd=premium-asia><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>About three dozen drugmakers will produce low-cost versions of Pfizer Inc.’s Covid-19 pill as part of an effort to expand supplies of the highly effective drug in lower-income regions.Those companies,...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2022-03-17/drugmakers-clinch-deals-to-boost-supplies-of-pfizer-s-covid-pill?srnd=premium-asia\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PFE","symbol_name":"辉瑞","start_time":0,"source_url":"https://www.bloomberg.com/news/articles/2022-03-17/drugmakers-clinch-deals-to-boost-supplies-of-pfizer-s-covid-pill?srnd=premium-asia","article_id":"1104468332","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1104468332","pubTimestamp":1647526833,"sourceInfo":{"source_id":"lsy1584095487587","name":"Bloomberg"},"weMediaInfo":null,"summary":"About three dozen drugmakers will produce low-cost versions of Pfizer Inc.’s Covid-19 pill as part o","collect":0,"end_time":0,"defaultTopTitle":"bloomberg.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"PFE":"辉瑞"},"translate_title":"制药商达成协议增加辉瑞Covid药丸的供应","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PFE":0.9},"content_text":"About three dozen drugmakers will produce low-cost versions of Pfizer Inc.’s Covid-19 pill as part of an effort to expand supplies of the highly effective drug in lower-income regions.Those companies, based in nations ranging from Bangladesh to Vietnam, will need to clear production and regulatory hurdles before the antiviral therapy can flow. A producer in Ukraine may join in making the drug, but hasn’t been able to sign an agreement because of Russia’s invasion.The United Nations-backed Medicines Patent Pool, which announced the accords on Thursday,said last weekthat manufacturers may be ready to supply the first pills by December. Larger quantities may only reach the market in May 2023, analytics firm Airfinity Ltd. estimates.Pfizer’s treatment, Paxlovid, slashed the risk of hospitalization or death by almost 90% in clinical trials and could play an important role in battling Covid with the disease still causing tens of thousands of deaths a week. A group of mostly richer countries have secured about a quarter of Pfizer’s initial supplies so far, heightening concern about access in lower-income nations, which were already left behind in getting vaccines.Pfizer won’t receive royalties from sales covered by the pact as long as Covid remains classified as an international public-health emergency by the World Health Organization, according to the patent pool.After the pandemic, middle-income nations will be subject to a 5% royalty for sales to the public sector and 10% for sales to the private sector. There will be no royalty payment for low-income countries.The agreements with 35 companies, which follows a licensing pact with Pfizer in November, paves the way for supplies to reach more than half the world’s population, according to a statement. The manufacturers include Teva Pharmaceutical Industries,Hikma PharmaceuticalsandCipla Ltd.Paxlovid consists of two drugs. The manufacturers will make generic versions of nirmatrelvir, a treatment that’s designed to block the action of a key enzyme that the virus uses to make copies of itself. That’s combined with HIV medication ritonavir, which helps slow the breakdown of the first drug, enabling it to remain active for longer and at higher concentrations.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9035132898,"gmtCreate":1647531206831,"gmtModify":1676534241469,"author":{"id":"4100143081992750","authorId":"4100143081992750","name":"fhho32","avatar":"https://community-static.tradeup.com/news/2e9d1fc00d659255c125be74d13236ea","vip":1,"crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"4100143081992750","idStr":"4100143081992750"},"htmlText":"Agree","listText":"Agree","text":"Agree","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9035132898","repostId":1104468332,"repostType":4,"repost":{"id":"1104468332","kind":"news","pubTimestamp":1647526833,"share":"https://ttm.financial/m/news/1104468332?lang=&edition=fundamental","pubTime":"2022-03-17 22:20","market":"us","language":"en","title":"Drugmakers Clinch Deals to Boost Supplies of Pfizer’s Covid Pill","url":"https://stock-news.laohu8.com/highlight/detail?id=1104468332","media":"Bloomberg","summary":"About three dozen drugmakers will produce low-cost versions of Pfizer Inc.’s Covid-19 pill as part o","content":"<html><head></head><body><p>About three dozen drugmakers will produce low-cost versions of Pfizer Inc.’s Covid-19 pill as part of an effort to expand supplies of the highly effective drug in lower-income regions.</p><p>Those companies, based in nations ranging from Bangladesh to Vietnam, will need to clear production and regulatory hurdles before the antiviral therapy can flow. A producer in Ukraine may join in making the drug, but hasn’t been able to sign an agreement because of Russia’s invasion.</p><p>The United Nations-backed Medicines Patent Pool, which announced the accords on Thursday,said last weekthat manufacturers may be ready to supply the first pills by December. Larger quantities may only reach the market in May 2023, analytics firm Airfinity Ltd. estimates.</p><p>Pfizer’s treatment, Paxlovid, slashed the risk of hospitalization or death by almost 90% in clinical trials and could play an important role in battling Covid with the disease still causing tens of thousands of deaths a week. A group of mostly richer countries have secured about a quarter of Pfizer’s initial supplies so far, heightening concern about access in lower-income nations, which were already left behind in getting vaccines.</p><p>Pfizer won’t receive royalties from sales covered by the pact as long as Covid remains classified as an international public-health emergency by the World Health Organization, according to the patent pool.</p><p>After the pandemic, middle-income nations will be subject to a 5% royalty for sales to the public sector and 10% for sales to the private sector. There will be no royalty payment for low-income countries.</p><p>The agreements with 35 companies, which follows a licensing pact with Pfizer in November, paves the way for supplies to reach more than half the world’s population, according to a statement. The manufacturers include Teva Pharmaceutical Industries,Hikma PharmaceuticalsandCipla Ltd.</p><p>Paxlovid consists of two drugs. The manufacturers will make generic versions of nirmatrelvir, a treatment that’s designed to block the action of a key enzyme that the virus uses to make copies of itself. That’s combined with HIV medication ritonavir, which helps slow the breakdown of the first drug, enabling it to remain active for longer and at higher concentrations.</p><p></p><p></p></body></html>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Drugmakers Clinch Deals to Boost Supplies of Pfizer’s Covid Pill</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDrugmakers Clinch Deals to Boost Supplies of Pfizer’s Covid Pill\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-17 22:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2022-03-17/drugmakers-clinch-deals-to-boost-supplies-of-pfizer-s-covid-pill?srnd=premium-asia><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>About three dozen drugmakers will produce low-cost versions of Pfizer Inc.’s Covid-19 pill as part of an effort to expand supplies of the highly effective drug in lower-income regions.Those companies,...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2022-03-17/drugmakers-clinch-deals-to-boost-supplies-of-pfizer-s-covid-pill?srnd=premium-asia\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.bloomberg.com/news/articles/2022-03-17/drugmakers-clinch-deals-to-boost-supplies-of-pfizer-s-covid-pill?srnd=premium-asia","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1104468332","content_text":"About three dozen drugmakers will produce low-cost versions of Pfizer Inc.’s Covid-19 pill as part of an effort to expand supplies of the highly effective drug in lower-income regions.Those companies, based in nations ranging from Bangladesh to Vietnam, will need to clear production and regulatory hurdles before the antiviral therapy can flow. A producer in Ukraine may join in making the drug, but hasn’t been able to sign an agreement because of Russia’s invasion.The United Nations-backed Medicines Patent Pool, which announced the accords on Thursday,said last weekthat manufacturers may be ready to supply the first pills by December. Larger quantities may only reach the market in May 2023, analytics firm Airfinity Ltd. estimates.Pfizer’s treatment, Paxlovid, slashed the risk of hospitalization or death by almost 90% in clinical trials and could play an important role in battling Covid with the disease still causing tens of thousands of deaths a week. A group of mostly richer countries have secured about a quarter of Pfizer’s initial supplies so far, heightening concern about access in lower-income nations, which were already left behind in getting vaccines.Pfizer won’t receive royalties from sales covered by the pact as long as Covid remains classified as an international public-health emergency by the World Health Organization, according to the patent pool.After the pandemic, middle-income nations will be subject to a 5% royalty for sales to the public sector and 10% for sales to the private sector. There will be no royalty payment for low-income countries.The agreements with 35 companies, which follows a licensing pact with Pfizer in November, paves the way for supplies to reach more than half the world’s population, according to a statement. The manufacturers include Teva Pharmaceutical Industries,Hikma PharmaceuticalsandCipla Ltd.Paxlovid consists of two drugs. The manufacturers will make generic versions of nirmatrelvir, a treatment that’s designed to block the action of a key enzyme that the virus uses to make copies of itself. That’s combined with HIV medication ritonavir, which helps slow the breakdown of the first drug, enabling it to remain active for longer and at higher concentrations.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9035107638,"gmtCreate":1647528650237,"gmtModify":1676534240972,"author":{"id":"3565832091209909","authorId":"3565832091209909","name":"HuatKueh313","avatar":"https://static.itradeup.com/news/fb2a3aa1007fa02bcad27f2593b66592","vip":1,"crmLevel":5,"crmLevelSwitch":1,"authorIdStr":"3565832091209909","idStr":"3565832091209909"},"htmlText":"Pls like","listText":"Pls like","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9035107638","repostId":1104468332,"repostType":4,"repost":{"id":"1104468332","kind":"news","pubTimestamp":1647526833,"share":"https://ttm.financial/m/news/1104468332?lang=&edition=fundamental","pubTime":"2022-03-17 22:20","market":"us","language":"en","title":"Drugmakers Clinch Deals to Boost Supplies of Pfizer’s Covid Pill","url":"https://stock-news.laohu8.com/highlight/detail?id=1104468332","media":"Bloomberg","summary":"About three dozen drugmakers will produce low-cost versions of Pfizer Inc.’s Covid-19 pill as part o","content":"<html><head></head><body><p>About three dozen drugmakers will produce low-cost versions of Pfizer Inc.’s Covid-19 pill as part of an effort to expand supplies of the highly effective drug in lower-income regions.</p><p>Those companies, based in nations ranging from Bangladesh to Vietnam, will need to clear production and regulatory hurdles before the antiviral therapy can flow. A producer in Ukraine may join in making the drug, but hasn’t been able to sign an agreement because of Russia’s invasion.</p><p>The United Nations-backed Medicines Patent Pool, which announced the accords on Thursday,said last weekthat manufacturers may be ready to supply the first pills by December. Larger quantities may only reach the market in May 2023, analytics firm Airfinity Ltd. estimates.</p><p>Pfizer’s treatment, Paxlovid, slashed the risk of hospitalization or death by almost 90% in clinical trials and could play an important role in battling Covid with the disease still causing tens of thousands of deaths a week. A group of mostly richer countries have secured about a quarter of Pfizer’s initial supplies so far, heightening concern about access in lower-income nations, which were already left behind in getting vaccines.</p><p>Pfizer won’t receive royalties from sales covered by the pact as long as Covid remains classified as an international public-health emergency by the World Health Organization, according to the patent pool.</p><p>After the pandemic, middle-income nations will be subject to a 5% royalty for sales to the public sector and 10% for sales to the private sector. There will be no royalty payment for low-income countries.</p><p>The agreements with 35 companies, which follows a licensing pact with Pfizer in November, paves the way for supplies to reach more than half the world’s population, according to a statement. The manufacturers include Teva Pharmaceutical Industries,Hikma PharmaceuticalsandCipla Ltd.</p><p>Paxlovid consists of two drugs. The manufacturers will make generic versions of nirmatrelvir, a treatment that’s designed to block the action of a key enzyme that the virus uses to make copies of itself. That’s combined with HIV medication ritonavir, which helps slow the breakdown of the first drug, enabling it to remain active for longer and at higher concentrations.</p><p></p><p></p></body></html>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Drugmakers Clinch Deals to Boost Supplies of Pfizer’s Covid Pill</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDrugmakers Clinch Deals to Boost Supplies of Pfizer’s Covid Pill\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-17 22:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2022-03-17/drugmakers-clinch-deals-to-boost-supplies-of-pfizer-s-covid-pill?srnd=premium-asia><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>About three dozen drugmakers will produce low-cost versions of Pfizer Inc.’s Covid-19 pill as part of an effort to expand supplies of the highly effective drug in lower-income regions.Those companies,...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2022-03-17/drugmakers-clinch-deals-to-boost-supplies-of-pfizer-s-covid-pill?srnd=premium-asia\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.bloomberg.com/news/articles/2022-03-17/drugmakers-clinch-deals-to-boost-supplies-of-pfizer-s-covid-pill?srnd=premium-asia","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1104468332","content_text":"About three dozen drugmakers will produce low-cost versions of Pfizer Inc.’s Covid-19 pill as part of an effort to expand supplies of the highly effective drug in lower-income regions.Those companies, based in nations ranging from Bangladesh to Vietnam, will need to clear production and regulatory hurdles before the antiviral therapy can flow. A producer in Ukraine may join in making the drug, but hasn’t been able to sign an agreement because of Russia’s invasion.The United Nations-backed Medicines Patent Pool, which announced the accords on Thursday,said last weekthat manufacturers may be ready to supply the first pills by December. Larger quantities may only reach the market in May 2023, analytics firm Airfinity Ltd. estimates.Pfizer’s treatment, Paxlovid, slashed the risk of hospitalization or death by almost 90% in clinical trials and could play an important role in battling Covid with the disease still causing tens of thousands of deaths a week. A group of mostly richer countries have secured about a quarter of Pfizer’s initial supplies so far, heightening concern about access in lower-income nations, which were already left behind in getting vaccines.Pfizer won’t receive royalties from sales covered by the pact as long as Covid remains classified as an international public-health emergency by the World Health Organization, according to the patent pool.After the pandemic, middle-income nations will be subject to a 5% royalty for sales to the public sector and 10% for sales to the private sector. There will be no royalty payment for low-income countries.The agreements with 35 companies, which follows a licensing pact with Pfizer in November, paves the way for supplies to reach more than half the world’s population, according to a statement. The manufacturers include Teva Pharmaceutical Industries,Hikma PharmaceuticalsandCipla Ltd.Paxlovid consists of two drugs. The manufacturers will make generic versions of nirmatrelvir, a treatment that’s designed to block the action of a key enzyme that the virus uses to make copies of itself. That’s combined with HIV medication ritonavir, which helps slow the breakdown of the first drug, enabling it to remain active for longer and at higher concentrations.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":634273054,"gmtCreate":1647528146269,"gmtModify":1676532861765,"author":{"id":"4091269729215160","authorId":"4091269729215160","name":"QQChai","avatar":"https://static.tigerbbs.com/31148e862df7412ae3c07fc206cad89c","vip":1,"crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"4091269729215160","idStr":"4091269729215160"},"htmlText":"Please like","listText":"Please like","text":"Please like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/634273054","repostId":1104468332,"repostType":4,"repost":{"id":"1104468332","kind":"news","pubTimestamp":1647526833,"share":"https://ttm.financial/m/news/1104468332?lang=&edition=fundamental","pubTime":"2022-03-17 22:20","market":"us","language":"en","title":"Drugmakers Clinch Deals to Boost Supplies of Pfizer’s Covid Pill","url":"https://stock-news.laohu8.com/highlight/detail?id=1104468332","media":"Bloomberg","summary":"About three dozen drugmakers will produce low-cost versions of Pfizer Inc.’s Covid-19 pill as part o","content":"<html><head></head><body><p>About three dozen drugmakers will produce low-cost versions of Pfizer Inc.’s Covid-19 pill as part of an effort to expand supplies of the highly effective drug in lower-income regions.</p><p>Those companies, based in nations ranging from Bangladesh to Vietnam, will need to clear production and regulatory hurdles before the antiviral therapy can flow. A producer in Ukraine may join in making the drug, but hasn’t been able to sign an agreement because of Russia’s invasion.</p><p>The United Nations-backed Medicines Patent Pool, which announced the accords on Thursday,said last weekthat manufacturers may be ready to supply the first pills by December. Larger quantities may only reach the market in May 2023, analytics firm Airfinity Ltd. estimates.</p><p>Pfizer’s treatment, Paxlovid, slashed the risk of hospitalization or death by almost 90% in clinical trials and could play an important role in battling Covid with the disease still causing tens of thousands of deaths a week. A group of mostly richer countries have secured about a quarter of Pfizer’s initial supplies so far, heightening concern about access in lower-income nations, which were already left behind in getting vaccines.</p><p>Pfizer won’t receive royalties from sales covered by the pact as long as Covid remains classified as an international public-health emergency by the World Health Organization, according to the patent pool.</p><p>After the pandemic, middle-income nations will be subject to a 5% royalty for sales to the public sector and 10% for sales to the private sector. There will be no royalty payment for low-income countries.</p><p>The agreements with 35 companies, which follows a licensing pact with Pfizer in November, paves the way for supplies to reach more than half the world’s population, according to a statement. The manufacturers include Teva Pharmaceutical Industries,Hikma PharmaceuticalsandCipla Ltd.</p><p>Paxlovid consists of two drugs. The manufacturers will make generic versions of nirmatrelvir, a treatment that’s designed to block the action of a key enzyme that the virus uses to make copies of itself. That’s combined with HIV medication ritonavir, which helps slow the breakdown of the first drug, enabling it to remain active for longer and at higher concentrations.</p><p></p><p></p></body></html>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Drugmakers Clinch Deals to Boost Supplies of Pfizer’s Covid Pill</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDrugmakers Clinch Deals to Boost Supplies of Pfizer’s Covid Pill\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-17 22:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2022-03-17/drugmakers-clinch-deals-to-boost-supplies-of-pfizer-s-covid-pill?srnd=premium-asia><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>About three dozen drugmakers will produce low-cost versions of Pfizer Inc.’s Covid-19 pill as part of an effort to expand supplies of the highly effective drug in lower-income regions.Those companies,...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2022-03-17/drugmakers-clinch-deals-to-boost-supplies-of-pfizer-s-covid-pill?srnd=premium-asia\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.bloomberg.com/news/articles/2022-03-17/drugmakers-clinch-deals-to-boost-supplies-of-pfizer-s-covid-pill?srnd=premium-asia","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1104468332","content_text":"About three dozen drugmakers will produce low-cost versions of Pfizer Inc.’s Covid-19 pill as part of an effort to expand supplies of the highly effective drug in lower-income regions.Those companies, based in nations ranging from Bangladesh to Vietnam, will need to clear production and regulatory hurdles before the antiviral therapy can flow. A producer in Ukraine may join in making the drug, but hasn’t been able to sign an agreement because of Russia’s invasion.The United Nations-backed Medicines Patent Pool, which announced the accords on Thursday,said last weekthat manufacturers may be ready to supply the first pills by December. Larger quantities may only reach the market in May 2023, analytics firm Airfinity Ltd. estimates.Pfizer’s treatment, Paxlovid, slashed the risk of hospitalization or death by almost 90% in clinical trials and could play an important role in battling Covid with the disease still causing tens of thousands of deaths a week. A group of mostly richer countries have secured about a quarter of Pfizer’s initial supplies so far, heightening concern about access in lower-income nations, which were already left behind in getting vaccines.Pfizer won’t receive royalties from sales covered by the pact as long as Covid remains classified as an international public-health emergency by the World Health Organization, according to the patent pool.After the pandemic, middle-income nations will be subject to a 5% royalty for sales to the public sector and 10% for sales to the private sector. There will be no royalty payment for low-income countries.The agreements with 35 companies, which follows a licensing pact with Pfizer in November, paves the way for supplies to reach more than half the world’s population, according to a statement. The manufacturers include Teva Pharmaceutical Industries,Hikma PharmaceuticalsandCipla Ltd.Paxlovid consists of two drugs. The manufacturers will make generic versions of nirmatrelvir, a treatment that’s designed to block the action of a key enzyme that the virus uses to make copies of itself. That’s combined with HIV medication ritonavir, which helps slow the breakdown of the first drug, enabling it to remain active for longer and at higher concentrations.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":9035103252,"gmtCreate":1647527405229,"gmtModify":1676534240821,"author":{"id":"4087721847289480","authorId":"4087721847289480","name":"manickam","avatar":"https://static.tigerbbs.com/e9da97ac4260e1d587068757e37599f4","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"4087721847289480","idStr":"4087721847289480"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9035103252","repostId":1104468332,"repostType":4,"repost":{"id":"1104468332","kind":"news","pubTimestamp":1647526833,"share":"https://ttm.financial/m/news/1104468332?lang=&edition=fundamental","pubTime":"2022-03-17 22:20","market":"us","language":"en","title":"Drugmakers Clinch Deals to Boost Supplies of Pfizer’s Covid Pill","url":"https://stock-news.laohu8.com/highlight/detail?id=1104468332","media":"Bloomberg","summary":"About three dozen drugmakers will produce low-cost versions of Pfizer Inc.’s Covid-19 pill as part o","content":"<html><head></head><body><p>About three dozen drugmakers will produce low-cost versions of Pfizer Inc.’s Covid-19 pill as part of an effort to expand supplies of the highly effective drug in lower-income regions.</p><p>Those companies, based in nations ranging from Bangladesh to Vietnam, will need to clear production and regulatory hurdles before the antiviral therapy can flow. A producer in Ukraine may join in making the drug, but hasn’t been able to sign an agreement because of Russia’s invasion.</p><p>The United Nations-backed Medicines Patent Pool, which announced the accords on Thursday,said last weekthat manufacturers may be ready to supply the first pills by December. Larger quantities may only reach the market in May 2023, analytics firm Airfinity Ltd. estimates.</p><p>Pfizer’s treatment, Paxlovid, slashed the risk of hospitalization or death by almost 90% in clinical trials and could play an important role in battling Covid with the disease still causing tens of thousands of deaths a week. A group of mostly richer countries have secured about a quarter of Pfizer’s initial supplies so far, heightening concern about access in lower-income nations, which were already left behind in getting vaccines.</p><p>Pfizer won’t receive royalties from sales covered by the pact as long as Covid remains classified as an international public-health emergency by the World Health Organization, according to the patent pool.</p><p>After the pandemic, middle-income nations will be subject to a 5% royalty for sales to the public sector and 10% for sales to the private sector. There will be no royalty payment for low-income countries.</p><p>The agreements with 35 companies, which follows a licensing pact with Pfizer in November, paves the way for supplies to reach more than half the world’s population, according to a statement. The manufacturers include Teva Pharmaceutical Industries,Hikma PharmaceuticalsandCipla Ltd.</p><p>Paxlovid consists of two drugs. The manufacturers will make generic versions of nirmatrelvir, a treatment that’s designed to block the action of a key enzyme that the virus uses to make copies of itself. That’s combined with HIV medication ritonavir, which helps slow the breakdown of the first drug, enabling it to remain active for longer and at higher concentrations.</p><p></p><p></p></body></html>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Drugmakers Clinch Deals to Boost Supplies of Pfizer’s Covid Pill</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDrugmakers Clinch Deals to Boost Supplies of Pfizer’s Covid Pill\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-17 22:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2022-03-17/drugmakers-clinch-deals-to-boost-supplies-of-pfizer-s-covid-pill?srnd=premium-asia><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>About three dozen drugmakers will produce low-cost versions of Pfizer Inc.’s Covid-19 pill as part of an effort to expand supplies of the highly effective drug in lower-income regions.Those companies,...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2022-03-17/drugmakers-clinch-deals-to-boost-supplies-of-pfizer-s-covid-pill?srnd=premium-asia\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.bloomberg.com/news/articles/2022-03-17/drugmakers-clinch-deals-to-boost-supplies-of-pfizer-s-covid-pill?srnd=premium-asia","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1104468332","content_text":"About three dozen drugmakers will produce low-cost versions of Pfizer Inc.’s Covid-19 pill as part of an effort to expand supplies of the highly effective drug in lower-income regions.Those companies, based in nations ranging from Bangladesh to Vietnam, will need to clear production and regulatory hurdles before the antiviral therapy can flow. A producer in Ukraine may join in making the drug, but hasn’t been able to sign an agreement because of Russia’s invasion.The United Nations-backed Medicines Patent Pool, which announced the accords on Thursday,said last weekthat manufacturers may be ready to supply the first pills by December. Larger quantities may only reach the market in May 2023, analytics firm Airfinity Ltd. estimates.Pfizer’s treatment, Paxlovid, slashed the risk of hospitalization or death by almost 90% in clinical trials and could play an important role in battling Covid with the disease still causing tens of thousands of deaths a week. A group of mostly richer countries have secured about a quarter of Pfizer’s initial supplies so far, heightening concern about access in lower-income nations, which were already left behind in getting vaccines.Pfizer won’t receive royalties from sales covered by the pact as long as Covid remains classified as an international public-health emergency by the World Health Organization, according to the patent pool.After the pandemic, middle-income nations will be subject to a 5% royalty for sales to the public sector and 10% for sales to the private sector. There will be no royalty payment for low-income countries.The agreements with 35 companies, which follows a licensing pact with Pfizer in November, paves the way for supplies to reach more than half the world’s population, according to a statement. The manufacturers include Teva Pharmaceutical Industries,Hikma PharmaceuticalsandCipla Ltd.Paxlovid consists of two drugs. The manufacturers will make generic versions of nirmatrelvir, a treatment that’s designed to block the action of a key enzyme that the virus uses to make copies of itself. That’s combined with HIV medication ritonavir, which helps slow the breakdown of the first drug, enabling it to remain active for longer and at higher concentrations.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":78,"commentSize":4,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}